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 Pre-clinical and early phase clinical
studies with remote ischemic
preconditioning (RIPC) appeared
promising; however, RIPC was not
effective in phase III clinical trials.
 To improve the translation of RIPC into
clinical practice, the kinetic properties
and functional effects of humoral factors
released after RIPC in humans were
characterized ex vivo.
 Venous blood from 20 healthy volunteers
was collected at baseline and 5 min,
30 min, 1 h, 6 h and daily from 1 to 7 days
after RIPC. Plasma dialysates were
infused into Langendorff-perfused mouse
hearts subjected to 20/120 min global
ischemia/reperfusion.
 Perfusion with dialysates obtained 5 min
to 6 days after RIPC signiﬁcantly
reduced infarct size by w50% when
compared to perfusion with dialysates
obtained at baseline prior to RIPC, and
increased STAT3 phosphorylation beyond
values obtained with baseline-dialysate.iversity of Essen Medical School,
Center Essen, University of Essen
SFB 1116 B8); IFORES 10þ2 (D/107-
rs have reported that they have no
d January 14, 2016.
ABBR EV I A T I ON S
AND ACRONYMS
AKT = protein kinase B
ERK = extracellular-regula
kinase
IQR = interquartile range
LVþRV = left and right
ventricular
LVDP = left ventricular
developed pressure
RIC = remote ischemic
conditioning
RIPC = remote ischemic
pre-conditioning
SAFE = survival activating
factor enhancement
STAT = signal transducer a
activator of transcription
TTC = 2,3,5-
triphenyltetrazolium chlori
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4SUMMARYted
nd
deAlthough remote ischemic pre-conditioning (RIPC) reduced infarct size in animal experiments and proof-of-concept
clinical trials, recent phase III trials failed to conﬁrm cardioprotection during cardiac surgery. Here, we characterized the
kinetic properties of humoral factors that are released after RIPC, as well as the signal transduction pathways that were
responsible for cardioprotection in an ex vivo model of global ischemia reperfusion injury. Venous blood from 20 healthy
volunteers was collected at baseline and 5 min, 30 min, 1 h, 6 h, and daily from 1 to 7 days after RIPC (3  5/5
min upper-limb ischemia/reperfusion). Plasma-dialysates (cut-off: 12 to 14 kDa; dilution: 1:20) were infused into
Langendorff-perfused mouse hearts subjected to 20/120 min global ischemia/reperfusion. Infarct size and phosphory-
lation of signal transducer and activator of transcription (STAT)3, STAT5, extracellular-regulated kinase 1/2 and protein
kinase B were determined. In a subgroup of plasma-dialysates, an inhibitor of STAT3 (Stattic) was used in mouse hearts.
Perfusion with baseline-dialysate resulted in an infarct size of 39% of ventricular mass (interquartile range: 36% to
42%). Perfusion with dialysates obtained 5 min to 6 days after RIPC signiﬁcantly reduced infarct size by w50% and
increased STAT3 phosphorylation beyond that with baseline-dialysate. Inhibition of STAT3 abrogated these effects.
These results suggest that RIPC induces the release of cardioprotective, dialyzable factor(s) within 5 min, and that
circulate for up to 6 days. STAT3 is activated in murine myocardium by RIPC-induced human humoral factors and is
causally involved in cardioprotection. (J Am Coll Cardiol Basic Trans Sci 2016;1:3–13) © 2016 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).R emote ischemic conditioning (RIC) with tran-sient limb ischemia/reperfusion is a noninva-sive method to protect the myocardium and
other parenchymal organs from ischemia/reperfusion
injury. Cardioprotection is achieved by RIC before
(pre-conditioning; RIPC), during (per-conditioning)
or after myocardial ischemia (post-conditioning) (1).
RIC has been demonstrated in many experimental
studies and also attenuates myocardial ischemia/
reperfusion injury in patients undergoing elective
interventional (2) or surgical coronary revasculariza-tion (3–5) as well as in patients with acute
myocardial infarction (6–10). The efﬁcacy of
RIC was evidenced by reduced cardiac
biomarker release (2–5,9) and reduced infarct
size on magnetic resonance imaging (6,8,10);
some smaller studies also reported improved
short- (5,8) and long-term clinical outcome
(2,4,7). However, the recent large-scaled,
randomized ERICCA (Effect of Remote
Ischaemic Preconditioning on Clinical Out-
comes in CABG Surgery) trial and RIPHeart
(Remote Ischaemic Preconditioning for Heart
Surgery) study in patients undergoing car-
diac surgery and ischemic cardioplegic arrest
failed to conﬁrm reduced biomarker release
and improved clinical outcome with RIPC
(11,12). Reasons for the failure of these trials
to conﬁrm protection by RIPC have been dis-
cussed in detail and related to confounding
variables (13–15), notably the use ofpropofol in the majority of all patients in both trials,
which might have abrogated the cardioprotective ef-
fect (16).
For more successful translation of experimental
animal studies and smaller proof-of-concept trials to
clinical reality a better understanding of RIC’s signal
transduction is mandatory. In particular, the transfer
signal from the remote peripheral organ where the
RIC maneuver is performed to the heart is still enig-
matic. Both neuronal and humoral transfer as well as
a neurohumoral interaction have been proposed.
Humoral transfer by nitrite (17), stromal cell–derived
factor-1a (18), and microRNA-144 (19) has been
reported. More systematic proteome analyses of
plasma taken after RIPC have not yet identiﬁed a
speciﬁc protein (20,21).
We therefore used another strategy to identify the
potential humoral transfer factor(s) by characterizing
their properties in kinetic terms and by the signal
activation which they elicit in the heart to effect
cardioprotection. Prior studies have reported a time
delay between the RIPC stimulus and the injurious
event from 5 to 10 min (22,23) to more than 24 h
(24–27), suggesting that RIPC is a fast acting as well as
a long-lasting phenomenon. Supporting the notion of
a long-lasting effect, ﬂow-mediated forearm vasodi-
lation in patients with reperfused acute myocardial
infarction was improved by RIPC for 1 week (28).
However, this particular study could not distinguish
whether there was a long-lasting circulation of trans-
fer factor(s) or a long-lasting effect in the target organ.
FIGURE 1 Experimental Setup for the Identiﬁcation of Humoral Transfer Factor(s) From Healthy Volunteers Undergoing RIPC to Isolated
Langendorff-Perfused Mouse Hearts
Plasma from 20 volunteers was obtained at 12 pre-deﬁned time points and dialyzed with a dilution of 1:20 for 24 h, using a cutoff of 12 to
14 kDa. After 20 min of stabilization, isolated mouse hearts were perfused with dialysates of human plasma for 15 min, followed by 5 min of
wash-out by perfusion with Krebs-Henseleit buffer, before undergoing 20 min of global ischemia. After 120 min of reperfusion, infarct size
was determined with 2,3,5-triphenyltetrazolium chloride (TTC) staining, and activation of proteins was analyzed with Western blot analysis.
D ¼ dialysate; d ¼ day; I ¼ ischemia; LVP ¼ left ventricular pressure; R ¼ reperfusion; RIPC ¼ remote ischemic pre-conditioning; S ¼ stabi-
lization; WO ¼ wash-out.
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5We have therefore obtained plasma from healthy
volunteers at different time points before and after a
RIPC maneuver and tested its cardioprotective effect
in a Langendorff-perfused mouse heart used as
bioassay. Cardioprotection relies on a complex signal
transduction of triggers, mediators, and effectors,
which also vary between different species (29). The
cytosolic signal transduction within the car-
diomyocyte includes the reperfusion injury salvage
kinase (SAFE) and the survival activating factor
enhancement systems (30), and both these systems
are also recruited for cardioprotection in mice (31–34).
We therefore went on to identify the signal trans-
duction, which was activated by the transfer of a hu-
man plasma-dialysate to achieve infarct size reduction
in the bioassay mouse heart.
METHODS
VOLUNTEER RECRUITMENT AND BLOOD SAMPLING.
The study was approved by the Institutional Review
Board (No.14-5995-BO) and conforms to the principles
of the Declaration of Helsinki. Written informed
consent was obtained from all volunteers. Twenty
nonsmoking healthy volunteers (10 men/10 women)were recruited between October 2014 and July 2015.
They had no history of disease or any medication
other than oral contraceptives in women.
RIPC was performed between 8 and 10 ante
meridiem independently from the day of the week.
The RIPC-maneuver consisted of 3 cycles of 5 min
upper-limb ischemia/inﬂation of a blood pressure
cuff to 200 mm Hg and reperfusion/deﬂation for
5 min. Venous blood samples from the contralateral
arm were obtained before RIPC (baseline) and at
5 min, 30 min, 1 h, 6 h, 1 day, and daily thereafter
until 7 days at the same time of day (Figure 1). The
blood was collected in heparinized tubes (S-Mon-
ovette 9 ml LH, SARSTEDT AG & Co., Nümbrecht,
Germany) and immediately centrifuged (Multifuge
3SR, Heraeus, Hanau, Germany) at 800 g for 20 min
at 4C. The plasma was separated and stored at
–80C until use.
ISOLATED MOUSE HEART PERFUSION. To assess the
cardioprotective effect of humoral factor(s) released
after RIPC from humans, a modiﬁed protocol of iso-
lated mouse heart perfusion was used (17). Mice
(C57Bl6/J; age: 8 to 12 weeks; weight: 20 to 30 g) were
purchased from Harlan Laboratories, Inc. (Horst, the
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6Netherlands) and from Charles River Laboratories
(Sulzfeld, Germany). The protocol was approved by
the governmental Animal Care and Use Committee
and conforms to the “Position of the American
Heart Association on Research Animal Use”, adopted
by the American Heart Association on November 11,
1984. After cervical dislocation, 200 IU of hepa-
rin (Heparin-Natrium-25000-ratiopharm, Ratiopharm
GmbH, Ulm, Germany) was intraperitoneally injected,
and hearts were excised. Within 2 min hearts were
cannulated (mouse heart cannula, Hugo Sachs Elek-
tronik, March-Hugstetten, Germany) under a stereo-
microscope (LS 6000IC, Beckman Coulter, Krefeld,
Germany) through the aorta in cold 0.9% NaCl solu-
tion and mounted on a Langendorff apparatus. At a
constant pressure of 100 mm Hg, hearts were
perfused with modiﬁed Krebs-Henseleit buffer, con-
taining (in mmol/l) 118 NaCl (AppliChem GmbH,
Darmstadt, Germany), 4.7 KCl, 1.64 MgSO4  7 H2O
(Merck, Darmstadt, Germany), 1.18 KH2PO4 (Merck,
Darmstadt, Germany), 2.00 Na-pyruvate, 5.55
glucose, 24.88 NaHCO3 (AppliChem GmbH, Darm-
stadt, Germany), and 2.5 mmol/l CaCl2. The
perfusate was ﬁltered through a 0.45 mm ﬁlter (Filter
Type HWAP, Merck, Darmstadt, Germany), oxygen-
ated and equilibrated to 37C before use. A
water-ﬁlled balloon made out of saran wrap (Top-
pits, Cofresco Frischhalteprodukte GmbH & Co. KG,
Minden, Germany) was inserted through the mitral
valve into the left ventricular cavity and connected to
a pressure transducer (DPT-6000, Pvb Codan, For-
stinning, Germany) to allow continuous monitoring
of left ventricular pressure. The left ventricular
end-diastolic pressure was initially set to 5 to 15
mm Hg, and hearts were paced at a constant rate of
500 beats/min (DPT-6000, Pvb Codan, Forstinning,
Germany) through a metallic clamp connected to the
cannula and a metallic needle inserted into the right
auricle (Figure 1).
Plasma (4 ml) was defrozen and centrifuged at
4.500 g for 10 min at 4C. The supernatant was placed
in a 12 to 14 kDa dialysis tubing (SpectraPor, Spec-
trum Europe B.V., Breda, the Netherlands) and dia-
lyzed for 24 h at 4C against a 20-fold volume of
modiﬁed Krebs-Henseleit buffer. Dialysates were
adjusted to 2.5 mmol/l CaCl2 and 24.88 mmol/l
NaHCO3, ﬁltered (5 mm Chromaﬁl Xtra PES-500/25,
Macherey-Nagel GmbH & Co. KG, Düren, Germany),
oxygenated and equilibrated to 37C before use
(Figure 1).
After a stabilization period of 20 min, hearts were
perfused with dialysate for 15 min, followed by 5 min
of wash-out with Krebs-Henseleit buffer to avoid
adherence of proteins from a stagnant dialysate tothe Langendorff apparatus or the coronary circula-
tion during its occlusion. The hearts were subjected
to 20 min global zero-ﬂow ischemia and 120 min
reperfusion with Krebs-Henseleit buffer. Peak and
end-diastolic left ventricular pressure and coronary
ﬂow (TS410 Ultraschall Flowmeter, Transonic Sys-
tems Inc., Ithaca, New York) were continuously
recorded (LabChart 8, LabChart, ADInstruments Pty
Ltd, Oxford, United Kingdom). Hearts with a left
ventricular developed pressure (LVDP) <50 mm Hg
and hearts with a coronary ﬂow <1 ml/min or
>5 ml/min after the stabilization period were dis-
carded. The median LVDP and coronary ﬂow of all
hearts perfused with dialysates of human plasma
obtained at the same time point after the RIPC
maneuver were calculated for every minute. LVDP
and coronary ﬂow of hearts perfused with baseline-
dialysates and of hearts perfused with post-RIPC-
dialysates were compared at the end of stabiliza-
tion (20 min), during perfusion with dialysate
(35 min), just before ischemia (40 min), at the end of
ischemia (60 min), at 15 min and 30 min of reperfusion
(75 min and 90 min of the protocol, respectively)
(Supplemental Figures 1 and 2).
INFARCT STAINING. After 120min reperfusion, hearts
were frozen at –20C for 30min and cut into 1 mm thick
slices (approximately 5 slices per heart). The slices
were immersed in 2,3,5-triphenyltetrazolium chloride
(TTC) solution (1% (w/V) dissolved in phosphate
buffer, consisting of 77.4% (V/V) 0.1 mol/l Na2HPO4
and 22.6% (V/V) 0.1 mol/l NaH2PO4), and incubated in
a water bath at 37C for 5 min. After photographing,
the slices were quickly frozen in liquid nitrogen and
stored at –80C for later analysis by Western blot.
Areas of viable tissue (red) and necrotic tissue (white)
were measured by computerized planimetry (ImageJ
1.48v, National Institutes of Health, Bethesda,
Maryland). Infarct size was calculated as percentage
of left and right ventricular (LVþRV) mass (% of
LVþRV).
Investigators performing infarct size quantiﬁcation
were blinded for Western blot analyses and vice
versa, and all were blinded for the experimental
protocols.
WESTERN BLOT ANALYSIS. Proteins of murine
myocardium were solubilized; protein lysates were
electrophoretically separated on pre-casted sodium
dodecyl sulfate-polyacrylamide electrophoresis
gels (BioRad, Munich, Germany) and transferred to
polyvinylidene ﬂuoride membranes. We used 30 mg
total protein for the detection of signal trans-
ducer and activator of transcription 3 (STAT3) and
extracellular-regulated kinase (ERK) 1/2 and 50 mg
FIGURE 2 Kinetics of Humoral Transfer Factor(s) as Evidenced by Reduction in Infarct Size
In isolated mouse hearts, dialysates of human plasma obtained between 5 min and 6 days after RIPC induced a reduction of infarct size,
as shown in the examples. Data are presented as median with interquartile ranges of n ¼ 20 at each time point; *p < 0.05 versus baseline.
d ¼ day; LVþRV ¼ left and right ventricle.
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7for the detection of STAT5 and protein kinase B
(AKT). After blocking, membranes were in-
cubated with antibodies—pSTAT3tyrosine705 (mouse,
monoclonal), pSTAT5tyrosine694 (rabbit, monoclonal),
pAKTserine473, pERK1/2threonine202/tyrosine204 (rabbit,
polyclonal)—all from Cell Signaling Technology, Inc.
(Danvers, Massachusetts) directed against the
phosphorylated forms of STAT3, STAT5, AKT, and
ERK1/2. After incubation with the respective sec-
ondary antibodies—antimouse (horse, polyclonal)
and antirabbit (goat, polyclonal)—both from Cell
Signaling Technology, Inc. (Danvers, Massachusetts),
immunoreactive signals were detected by chem-
iluminescence (SuperSignal West Femto, Thermo
Fisher Scientiﬁc, Rockford, Illinois) using a
charge-coupled device camera (ChemoCam INTAS,
Göttingen, Germany) and quantiﬁed with LabIm-
age1D (INTAS, Göttingen, Germany). Membranes
were reprobed for detection of the respective total
form of each protein—STAT3 (rabbit, monoclonal),
STAT5, AKT, ERK1/2 (rabbit, polyclonal)—all from Cell
Signaling Technology, Inc. (Danvers, Massachusetts).
Immunoreactivities of phosphorylated proteins were
normalized to those of the total form of the respec-
tive protein.IN VITRO STAT3 INHIBITION. Further investigation
of the SAFE pathway was performed by inhibition of
STAT3 using Stattic (Stattic, Tocris bioscience, Bristol,
England) (35,36). Plasma from 7 volunteers taken at
3 time points was tested for this in vitro inhibition of
the SAFE pathway: baseline, 30 min and 6 days after
RIPC. Stattic was dissolved in dimethylsulfoxide and
added to the Krebs-Henseleit buffer at a ﬁnal
concentration of 10 mmol/l and a ﬁnal dilution of
dimethylsulfoxide of 1:10.000. After stabilization for
20 min, mouse hearts were pre-treated with
Stattic-containing Krebs-Henseleit buffer for 20 min,
followed by perfusion with human dialysate. During
wash-out and reperfusion, plain Krebs-Henseleit
buffer was used again. After TTC staining the slices
of the hearts were immunoblotted to verify successful
STAT3 inhibition.
STATISTICAL ANALYSIS. Most Western blot data
failed normality and equal variance test, therefore
all continuous variables are presented as median and
interquartile range (IQR) and categorical variables as
frequencies and percentages. Comparisons were
made between hearts perfused with dialysates of
plasma obtained at baseline and hearts perfused
with dialysates of plasma obtained at the
FIGURE 3 LVDP and Coronary Flow at 15 Min Reperfusion of Isolated Mouse Hearts
(A) Improvement of left ventricular developed pressure (LVDP) by perfusion with dialysates of human plasma obtained after RIPC compared to
dialysates of human plasma obtained at baseline. (B) Coronary ﬂow was not affected. Data are median with interquartile ranges of n ¼ 20 at
each time point; *p < 0.05 versus baseline. d ¼ day; CF ¼ coronary ﬂow.
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8pre-deﬁned time points after RIPC. Statistical anal-
ysis was performed using Friedman repeated mea-
sures analysis of variance on ranks with post hoc
Dunn’s method. A p value <0.05 was considered
statistically signiﬁcant. All statistical analyses were
performed using SPSS software (SigmaStat 3.5, SPSS,
Chicago, Illinois).
RESULTS
Volunteer demographics are presented in
Supplemental Table 1. There were no protocol de-
viations or adverse events.
INFARCT SIZE REDUCTION AND IMPROVEMENT IN
LVDP. Perfusion with dialysates of human plasma
obtained at baseline resulted in an infarct size of
39% of LVþRV (IQR: 36% to 42%). Perfusion with
dialysates of human plasma obtained within the
pre-speciﬁed time points between 5 min and 6 days
after RIPC reduced infarct size in comparison to
that with baseline dialysate (Figure 2). Dialysates of
plasma obtained 5 min after RIPC reduced infarct
size to 28% of LVþRV (IQR: 22% to 35%), and
minimal infarct size was observed with dialysates
of plasma obtained 2 days after RIPC (i.e., 18% of
LVþRV [IQR: 13% to 27%]. While dialysates of
human plasma obtained 6 days after the RIPC
maneuver still reduced infarct size to 24% of
LVþRV (IQR: 18% to 27%), dialysates of plasma
obtained 7 days after the RIPC maneuver did not(i.e., infarct size was 32% of LVþRV [IQR: 22% to
37%]) (Figure 2). LVDP was signiﬁcantly improved
at 15 min reperfusion by post-RIPC-dialysates
compared to baseline-dialysate, while coronary
ﬂow was not different at any time point (Figure 3,
Supplemental Figures 1 and 2).
SIGNAL ACTIVATION. In murine myocardium dialy-
sates of plasma obtained after RIPC induced an
increase of STAT3 phosphorylation over that with
baseline-dialysate (p ¼ 0.01) (Figure 4A). The phos-
phorylation of STAT5 (p ¼ 0.07) showed a similar ten-
dency, while phosphorylation of AKT (p ¼ 0.76)
and ERK1/2 (p ¼ 0.38) was not affected (Figures 4B
to 4D). Examples of Western blot membranes and
the respective chemiluminescence signals are dis-
played in the supplemental appendix for each protein
(Supplemental Figure 3).
STAT3 INHIBITION. Infarct size reduction and
STAT3 activation were abolished by Stattic
(Figure 5). Infarct sizes of hearts perfused with di-
alysates of plasma obtained 30 min after RIPC
were increased by pre-treatment with Stattic
(19% of LVþRV [IQR: 16% to 29%] to 45% of LVþRV
[IQR: 41% to 46%], p < 0.05) (Figure 5A). The
same was true for hearts perfused with dialysates
of plasma obtained 6 days after RIPC (25% of
LVþRV [IQR: 23% to 29%] to 40% of LVþRV [IQR:
38% to 45%], p < 0.05) (Figure 5A). Stattic had
no inﬂuence on infarct size per se (42% of LVþRV
FIGURE 4 STAT3 Phosphorylation in Murine Myocardium After Infusion of Human Plasma Dialysates Obtained Before and After RIPC
Time courses of phosphorylation of (A) signal transducer and activator of transcription 3 (STAT3), (B) STAT5, (C) protein kinase B (AKT), and (D)
extracellular-regulated kinase 1/2 (ERK1/2) in murine myocardium perfused with human plasma-dialysates obtained at baseline (before) as well
as at different time points after RIPC and exemplaryWestern blots, respectively. Data are presented as median with interquartile ranges of n¼ 20
at each time point; *p < 0.05 versus baseline. d ¼ day; RIPC ¼ remote ischemic pre-conditioning; Ser ¼ serine; Thr ¼ threonine; Tyr ¼ tyrosine.
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FIGURE 5 STAT3 Inhibition With Stattic Abolished the Protection by Dialysates of Human Plasma Obtained After RIPC in
Murine Myocardium
(A) Effect of Stattic (signal transducer and activator of transcription 3 [STAT3] inhibitor) on infarct size and (B) STAT3 phosphorylation in
murine myocardium perfused with dialysates of human plasma obtained before (baseline) as well as 30 min and 6 days after RIPC for n ¼ 7
each; *p < 0.05 versus without Stattic. d ¼ day; LVþRV ¼ left and right ventricle; RIPC ¼ remote ischemic pre-conditioning; Tyr ¼ tyrosine.
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10[IQR: 40% to 43%] vs. 39% of LVþRV [IQR: 34%
to 48%], p ¼ NS) (Figure 5A). Stattic did not
change LVDP and coronary ﬂow (Supplemental
Figure 4). The efﬁcacy of STAT3 inhibition by
Stattic was veriﬁed by the reduced STAT3 phos-
phorylation at baseline, 30 min, and 6 days after
RIPC (pSTAT3/total STAT3: 1.02 [IQR: 0.87 to 1.12]
to 0.45 [IQR: 0.40 to 0.54], 0.94 [IQR: 0.90 to 1.04]
to 0.37 [IQR: 0.31 to 0.44], and 0.95 [IQR: 0.78 to 1.
11] to 0.42 [IQR: 0.35 to 0.51], respectively)
(Figure 5B). Original Western blot results and the
respective chemiluminescence signals are displayed
in the supplemental appendix (Supplemental
Figure 5).
DISCUSSION
The present study characterized the kinetics and
identiﬁed a signal transduction property of humoral
factor(s) after a single RIPC-maneuver in healthy
volunteers. The dialysate of human plasma obtained
at 5 min and thereafter until at least 6 days after the
RIPC-maneuver was transferred to a Langendorff-
perfused mouse heart where it reduced infarct size
from global ischemia/reperfusion through STAT3
activation.KINETICS OF HUMORAL FACTOR(S). The release
of a circulating factor with a rapid onset of cardio-
protection in the bioassay heart of the present study
is consistent with prior experimental and clinical
studies, which revealed evidence for protection with
an interval of only 5 to 10 min between the RIPC
stimulus and the injurious event (22,23,37,38).
The continuous presence of a circulating factor
that provides cardioprotection in the bioassay
mouse heart in the present study is again consistent
with prior experimental and clinical studies,
which revealed evidence of long-lasting protection
(24,26,27,39) for up to 1 week after the RIPC stimulus
(28). In contrast to our present study, however, these
studies could not distinguish between a long-lasting
presence of a circulating factor or a long-lasting
protective effect in the target organ. Given the dilu-
tion of the circulating factor that we had to use for
technical reasons to perfuse the mouse heart with a
dialysate, the appearance of a circulating factor
which initiates protection may even be faster and last
longer than we observed. However, we cannot
distinguish whether we are dealing with the rapid
and continuous release of a factor with a short
half-life or a rapid release of a factor with a long
half-life. Also, we have no information whether we
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: RIPC protects
against myocardial ischemia/reperfusion injury in animal studies
and clinical proof-of-concept trials. Recent large-scaled,
randomized trials did not conﬁrm protection by RIPC in patients
undergoing cardiac surgery, possibly because of confounding
comorbidities and medications. The deﬁnition of basic charac-
teristics of RIPC-induced cardioprotection in healthy volunteers
may help to design future clinical trials.
TRANSLATIONAL OUTLOOK 1: The kinetics and signaling of
cardioprotection by RIPC must be better deﬁned.
TRANSLATIONAL OUTLOOK 2: Identiﬁcation of the transfer
factor(s) is mandatory for its potential use as a therapeutic agent.
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11are dealing with a single factor or a combination of
factors.
In the present study, we have not investigated
potential candidate molecules—nitrite (17), stromal
cell–derived factor-1a (18), and microRNA-144 (19)—in
the dialysate. However, with a pore size of #5 nm of
the dialysis tubing, exosomes that also contribute to
protection by RIPC (40) are excluded, unless they
have released their protective molecules during the
dialysis procedure.
SIGNAL ACTIVATION IN MURINE MYOCARDIUM. In
murine myocardium cardioprotection by local
ischemic conditioning is associated with the activation
of AKT, STAT3, and STAT5 (31,32,35,41); RIPC in mice
has been shown to be associated with the activation
of ERK1/2, AKT, and STAT3 (42,43). Apparently, in our
present study the humoral factor(s) obtained from
healthy volunteers after a single RIPC maneuver
activated only STAT3 signiﬁcantly whereas AKT
and ERK1/2 were not activated and STAT5 only
nonsigniﬁcantly. The STAT3 activation was causal for
infarct size reduction since Stattic abrogated the pro-
tection. Although not signiﬁcant, the trend for an acti-
vation of STAT5 is noteworthy because STAT5 is the
only signaling protein, which has so far been demon-
strated to be activated by RIPC in human tissue (44).
The activation of STAT3 points to members of the
cytokine and/or the growth hormone family as potential
circulating RIPC transfer factor(s), as both cytokines and
growth hormones classically activate the STAT3 and
also the STAT5 pathway (29,45,46). We did not inves-
tigate the signal transduction downstream of STAT3
activation. However, the causal role of STAT3 in the
rapid infarct size reduction (within 30 min) precludes a
role of STAT3 as a transcription factor, which in turn
may interact with other cardioprotective transcription
factors such as hypoxia-inducible factors (47,48), for the
present study. The causal role of STAT3 is rather
attributable to better mitochondrial function, as we
have shown before in protocols of ischemic
post-conditioning (35,36).
STUDY LIMITATIONS. We used a saline-perfused
Langendorff heart preparation with all its limitations,
including the development of edema. The human
factor(s) in the present study were obtained fromhealthy volunteers but protection and its signal
transduction were only identiﬁed after inter-species
transfer in the isolated mouse heart. The humoral
factor(s) may be different in kinetics and properties in
patients with cardiovascular disease, con-
founding co-morbidities and comedications. Also, the
signal transduction and the protective effect may
be quantitatively and qualitatively different in
the diseased human than the healthymouse heart (13).
CONCLUSIONS
A single RIPC maneuver in healthy volunteers in-
duces release of 1 or more cardioprotective, dialyz-
able, humoral factors that circulate already after 5
min and for up to 6 days. These factors reduce infarct
size through STAT3 activation in the mouse heart.
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